Neisseria meningitidis B vaccines: recent advances and possible immunization policies

References

• Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2011;344(18):1378-88
   Google Scholar
• World Health Organization (WHO). Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011;86(47):521-39
   PubMedGoogle Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012;799:1-20
   PubMedGoogle Scholar
• Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines 2011;10(9):1337-51
   PubMed Web of Science ®Google Scholar
• Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012;30(Suppl 2):B26-36
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2(8346):355-7
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972;126(5):514-21
   PubMed Web of Science ®Google Scholar
• Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010;50(Suppl 2):S54-65
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd B, Zomer G, van den Ijssel J, et al. Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development. PLoS One 2013;8(1):e54314
   PubMed Web of Science ®Google Scholar
• Segal S, Pollard AJ. Vaccines against bacterial meningitis. Br Med Bull 2005;72:65-81
   PubMedGoogle Scholar
• Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14(2):195-207; discussion 208-210
   PubMedGoogle Scholar
• Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique. Chile. Vaccine 1995;13(9):821-9
   PubMed Web of Science ®Google Scholar
• Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14(2):67-79; discussion 79-80
   PubMedGoogle Scholar
• Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166(7):817-23
   PubMed Web of Science ®Google Scholar
• Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009;38(2):413-18
   PubMed Web of Science ®Google Scholar
• Caron F, du Châtelet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011;11(6):455-63
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010;362(16):1511-20
   PubMed Web of Science ®Google Scholar
• Fisseha M, Chen P, Brandt B, et al. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect Immun 2005;73(7):4070-80
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19(17-19):2688-91
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287(5459):1816-20
   PubMed Web of Science ®Google Scholar
• Donati C, Rappuoli R. Reverse vaccinology in the 21st century: improvements over the original design. Ann NY Acad Sci 2013;1285:115-32
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103(29):10834-9
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, Bexsero®: immunological, functional and structural characterization of the antigens. Vaccine 2012;30(Suppl 2):B87-97
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Bexsero. Authorization details. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002333/human_med_001614.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Australian Government. Department of Health, Therapeutic Goods Administration. ARTG ID 190718. Available from: http://search-au.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=190718
   Google Scholar
• Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177(1):501-10
   PubMed Web of Science ®Google Scholar
• Hakobyan S, Tortajada A, Harris CL, et al. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int 2010;78(8):782-8
   PubMedGoogle Scholar
• Lucidarme J, Tan L, Exley RM, et al. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 2011;18(6):1002-14
   PubMedGoogle Scholar
• Welsch JA, Ram S, Koeberling O, Granoff DM. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008;197(7):1053-61
   PubMedGoogle Scholar
• Seib KL, Serruto D, Delany I, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009;77(1):292-9
   PubMed Web of Science ®Google Scholar
• Koeberling O, Delany I, Granoff DM. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 2011;18(5):736-42
   PubMedGoogle Scholar
• Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003;197(6):789-99
   PubMed Web of Science ®Google Scholar
• Bambini S, Muzzi A, Olcen P, et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009;27(21):2794-803
   PubMed Web of Science ®Google Scholar
• Vu DM, Pajon R, Reason DC, Granoff DM. A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp. Sci Rep 2012;2:341
   PubMedGoogle Scholar
• Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009;155(Pt 9):2873-83
   PubMedGoogle Scholar
• Gorringe AR, Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother 2012;8(2):174-83
   PubMed Web of Science ®Google Scholar
• Linke DT, Riess T, Autenrieth IB, et al. Trimeric autotransporter adhesins: variable structure, common function. Trends Microbiol 2006;14(6):264-70
   PubMed Web of Science ®Google Scholar
• Franzoso S, Mazzon C, Sztukowska M, et al. Human monocytes/macrophages are a target of Neisseria meningitidis adhesin A (NadA). J Leukoc Biol 2008;83(5):1100-10
   PubMedGoogle Scholar
• Capecchi B, Serruto D, Adu-Bobie J, et al. The genome revolution in vaccine research. Curr Issues Mol Biol 2004;6(1):17-27
   PubMedGoogle Scholar
• Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195(11):1445-54
   PubMed Web of Science ®Google Scholar
• Metruccio MM, Pigozzi E, Roncarati D, et al. A novel PHA variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 2009;5(12):e1000710
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010;17(6):919-29
   PubMed Web of Science ®Google Scholar
• Montanari P, Bozza G, Capecchi B, et al. Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion. Cell Microbiol 2012;14(3):368-85
   PubMedGoogle Scholar
• Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010;107(8):3770-5
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51(10):1127-37
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis. 2086 lipoprotein. Infect Immun 2004;72(4):2088-100
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010;28(9):2122-9
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, et al. Sequence diversity of vaccine candidate LP2086 in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009;200(3):379-389
   Google Scholar
• Caesar NM, Myers KA, Fan X. Neisseria meningitidis serogroup B vaccine development. Microb Pathog 2013;57:33-40
   PubMed Web of Science ®Google Scholar
• Vermont CL, van Dijken HH, Kuipers AJ, et al. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun 2003;71(4):1650-5
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Labadie J, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane- vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 2000;18(15):1456-66
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Lafeber AB, et al. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J Infect Dis 2001;184(1):98-102
   PubMedGoogle Scholar
• de Kleijn ED, de Groot R, Lafeber AB, et al. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 2000;19(9-10):1141-8
   PubMed Web of Science ®Google Scholar
• Peeters CC, Rumke HC, Sundermann LC, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14(10):1009-15
   PubMed Web of Science ®Google Scholar
• Cartwright K, Morris R, Rümke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17(20-21):2612-19
   PubMed Web of Science ®Google Scholar
• Kaaijk P, van Straaten I, van de Waterbeemd B, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 2013;31(7):1065-71
   PubMed Web of Science ®Google Scholar
• Rots NY, Kleijne DE. Safety of a nonavalent meningococcal serogroup B vaccine in healthy adult volunteers in a randomised, controlled, single blind study. Presented at: 16th International Pathogenic Neisseria Conference; 7–12 September 2008; Rotterdam, The Netherlands
   Google Scholar
• Steeghs L, Tommassen J, Leusen JH, et al. Teasing apart structural determinants of ‘toxicity’ and ‘adjuvanticity’: implications for meningococcal vaccine development. J Endotoxin Res 2004;10(2):113-19
   PubMedGoogle Scholar
• Koeberling O, Seubert A, Granoff DM. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008;198(2):262-70
   PubMedGoogle Scholar
• van der Ley P, Steeghs L, Hamstra HJ, et al. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 2001;69(10):5981-90
   PubMed Web of Science ®Google Scholar
• Koeberling O, Giuntini S, Seubert A, Granoff DM. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009;16(2):156-62
   PubMedGoogle Scholar
• van de Waterbeemd B, Streefland M, van der Ley P, et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 2010;28(30):4810-16
   PubMedGoogle Scholar
• Stoddard MB, Pinto V, Keiser PB, Zollinger W. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin Vaccine Immunol 2010;17(1):98-107
   PubMedGoogle Scholar
• Kaaijk P, van der Ark AA, van Amerongen G, van den Dobbelsteen GP. Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers. J Appl Toxicol 2013;33(6):521-6
   PubMedGoogle Scholar
• Hou VC, Koeberling O, Welsch JA, Granoff DM. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived Neisserial antigen. 1870. J Infect Dis 2005;192(4):580-90
   PubMedGoogle Scholar
• Koeberling O, Welsch JA, Granoff DM. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen. 1870;Vaccine 2007;25(10):1912-20
   Google Scholar
• Zollinger WD, Donets MA, Schmiel DH, et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 2010;28(31):5057-67
   PubMedGoogle Scholar
• Koeberling O, Seubert A, Santos GF, et al. A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor H binding protein elicits broad serum bactericidal antibody responses in infant rhesus monkeys. Presented at: International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada
   Google Scholar
• Keiser PB, Gibbs BT, Coster TS, et al. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 2010;28(43):6970-6
   PubMed Web of Science ®Google Scholar
• Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011;29(7):1413-20
   PubMed Web of Science ®Google Scholar
• Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997;185(7):1173-83
   PubMed Web of Science ®Google Scholar
• Giuntini S, Vu DM, Granoff DM. fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. Vaccine 2013;31(38):4192-9
   PubMedGoogle Scholar
• Lewis LA, Ngampasutadol J, Wallace R, et al. The meningococcal vaccine candidate Neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 2010;6(7):e1001027
   PubMed Web of Science ®Google Scholar
• Cadieux N, Plante M, Rioux CR, et al. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun 1999;67(9):4955-9
   PubMed Web of Science ®Google Scholar
• Martin D, Brodeur BR, Hamel J, et al. Candidate Neisseria meningitidis NspA vaccine. J Biotechnol 2000;83(1-2):27-31
   PubMed Web of Science ®Google Scholar
• Stork M, Bos MP, Jongerius I, et al. An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential. PLoS Pathog 2010;6:e1000969
   PubMed Web of Science ®Google Scholar
• Hubert K, Devos N, Mordhorst I, et al. ZnuD, a potential candidate for a simple and universal Neisseria meningitidis vaccine. Infect Immun 2013;81(6):1915-27
   PubMed Web of Science ®Google Scholar
• Voulhoux R, Tommassen J. Omp85, an evolutionarily conserved bacterial protein involved in outer-membrane-protein assembly. Res Microbiol 2004;155(3):129-35
   PubMedGoogle Scholar
• Peeters CC, Claassen IJ, Schuller M, et al. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice. Vaccine 1999;17(20-21):2702-12
   PubMed Web of Science ®Google Scholar
• Claassen I, Meylis J, van der Ley P, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996;14(10):1001-8
   PubMedGoogle Scholar
• Martin DR, Ruijne N, McCallum L, et al. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006;13(4):486-91
   PubMedGoogle Scholar
• Wedege E, Hoiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 1998;66(7):3223-31
   PubMed Web of Science ®Google Scholar
• Wedege E, Lie K, Bolstad K, et al. Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice. Scand J Immunol 2013;77(6):452-9
   PubMed Web of Science ®Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27(Suppl 2):B112-16
   PubMed Web of Science ®Google Scholar
• Qin L, Gilbert PB, Corey L, et al. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007;196(9):1304-12
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization – international meeting report Emory University, Atlanta, Georgia, United States. 16-17 March. 2005. Vaccine 2006;24(24):5093-107
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009;27(Suppl 2):B3-B12
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005;23(17-18):2222-7
   PubMed Web of Science ®Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011;18(3). 483-6
   PubMed Web of Science ®Google Scholar
• Taha MK, Deghmane AE. New recombinant vaccines for the prevention of meningococcal B disease. New recombinant vaccines for the prevention of meningococcal B disease. Vaccine Dev Ther 2012;2:15-22
   Google Scholar
• Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011;11(7):969-85
   PubMed Web of Science ®Google Scholar
• Richmond PC, Nissen MD, Marshall HS, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 2012;30(43):6163-74
   PubMed Web of Science ®Google Scholar
• Sheldon EA, Schwartz H, Jiang Q, et al. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother 2012;8(7):888-95
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013;31(12):1569-75
   PubMed Web of Science ®Google Scholar
• Nissen MD, Marshall HS, Richmond PC, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013;32(4):364-71
   PubMedGoogle Scholar
• Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12(8):597-607
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 2012;31(10):1061-1068
   Google Scholar
• Toneatto D, Oster P, deBoer AC, et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 2011;7(7):781-91
   PubMed Web of Science ®Google Scholar
• Toneatto D, Ismaili S, Ypma E, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (Bexsero®) in humans. Hum Vaccin 2011;7(6):646-53
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (Bexsero®) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379(9816):617-24
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 mo after immunization with one, two or three doses of Bexsero® meningococcal serogroup B vaccine. Hum Vaccin Immunother 2013;9(11):2304-10
   PubMed Web of Science ®Google Scholar
• Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 2013;185(15):E715-24
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29(11):e71-9
   Google Scholar
• Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J 2013;32(10):1116-21
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307(6):573-82
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381(9869):825-35
   PubMed Web of Science ®Google Scholar
• Halperin SA, Langley JM, Smith B, et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2007;25(3):450-7
   PubMed Web of Science ®Google Scholar
• Boccadifuoco G, Brunelli B, Pizza MG, Giuliani MM. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine. J Prev Med Hyg 2012;53(2):56-60
   PubMedGoogle Scholar
• Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107(45):19490-5
   PubMed Web of Science ®Google Scholar
• Snape MD, Medini D, Halperin SA, et al. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012;30(Suppl 2):B67-72
   PubMed Web of Science ®Google Scholar
• Plikaytis BD, Stella M, Boccadifuoco G, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012;19(10):1609-17
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013;13(5):416-25
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Halperin SA, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013;32(1):124-30
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Sapio ML, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31(43):4968-74
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010;28(37):6086-93
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007;31(1):101-7
   PubMed Web of Science ®Google Scholar
• Hong E, Giuliani MM, Deghmane AE, et al. Could the multicomponent meningococcal serogroup B vaccine (Bexsero®) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 2013;31(7):1113-16
   PubMed Web of Science ®Google Scholar
• Harris SL, Zhu D, Murphy E, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Hum Vaccin 2011;7(Suppl):68-74
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Hak E, van der Ende A, et al. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother 2013;9(5):1129-38
   PubMed Web of Science ®Google Scholar
• Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modeling study of potential impact. Vaccine 2013;31(23):2638-46
   PubMed Web of Science ®Google Scholar
• Bos JM, Rümke HC, Welte R, et al. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands. Pharmacoeconomics 2006;24(2):141-53
   PubMedGoogle Scholar
• Prymula R, Esposito S, Kittel C, et al. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. Presented at 29th European Society for Paediatric Infectious Diseases (ESPID) Annual meeting; 7–11 June 2011; The Hague, the Netherlands
   Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005;162(1):89-100
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197(5):737-43
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM; UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359(9320):1829-31
   PubMed Web of Science ®Google Scholar
• Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario. Canada, 2000-2006. Vaccine 2009;27(11):1735-40
   PubMedGoogle Scholar
• Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013;56(3):354-63
   PubMed Web of Science ®Google Scholar
• Delbos V, Lemée L, Bénichou J, et al. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine 2013;31(40):4416-20
   PubMed Web of Science ®Google Scholar
• Bjune G. “Herd immunity” and the meningococcal vaccine trial in Norway. Lancet 1992;340(8814):315
   PubMed Web of Science ®Google Scholar
• Perkins BA, Jonsdottir K, Briem H, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998;177(3):683-91
   PubMedGoogle Scholar
• A phase 3 observer blind randomized, multi-center, controlled study to evaluate the effect of Novartis vaccine's meningococcal B recombinant and menACWY conjugate vaccines on pharyngeal carriage of N. meningitidis in young adults. Available from: http://clinicaltrials.gov/show/NCT01214850
   Google Scholar
• Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008;26(3):191-215
   PubMed Web of Science ®Google Scholar
• UK Joint Committee on Vaccination and Immunisation (JCVI). JCVI interim position statement on use of Bexsero® meningococcal B vaccine in the UK. Available from: www.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf
   Google Scholar
• Taha MK. Immunisation against meningococcus B. Lancet 2013;382(9896):936
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: Annual epidemiological report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data. ECDC; Stockholm, Sweden: 2013. p. 168-72
   Google Scholar
• Bettinger JA, Deeks SL, Halperin SA, et al. Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines 2013;12(5):505-17
   PubMed Web of Science ®Google Scholar
• Buttery JP, Riddell A, McVernon J, et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 2005;293(14):1751-8
   PubMed Web of Science ®Google Scholar
• Committee on Infectious Diseases, 1998–1999. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Pediatrics 1999;103(5 Pt 1):1064-77
   PubMedGoogle Scholar
• Phase 2, observer blinded, controlled, randomized multi-center study in adolescents, to evaluate safety, tolerability and immunogenicity of four different rMenB plus menACWY Formulations. Available from: www.clinicaltrials.gov/ct2/show/NCT01210885?term=NCT01210885&rank=1139
   Google Scholar